US Patent

US8598227 — Epoprostenol formulation and method of making thereof

Other · Assigned to Actelion Pharmaceuticals Ltd · Expires 2027-02-02 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a stable epoprostenol composition that can be combined with IV fluids and stored at room temperature for over 24 hours.

USPTO Abstract

This invention relates to a stable epoprostenol composition that can be combined with commercially available IV fluids and can be administered in its reconstituted and/or diluted form under ambient conditions of about 15-30° C. for greater than 24 hours. The composition preferably contains (a) epoprostenol or a salt thereof; (b) a alkalinization agent; and (c) a base, such that when reconstituted or in solution, the solution has a pH>11. Methods for making the lyophilized composition are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US8598227
Jurisdiction
US
Classification
Other
Expires
2027-02-02
Drug substance claim
No
Drug product claim
No
Assignee
Actelion Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.